Rice Hall James & Associates LLC Sells 10,756 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Rice Hall James & Associates LLC decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,656 shares of the biotechnology company's stock after selling 10,756 shares during the period. Ascendis Pharma A/S comprises approximately 1.2% of Rice Hall James & Associates LLC's holdings, making the stock its 19th largest position. Rice Hall James & Associates LLC owned about 0.26% of Ascendis Pharma A/S worth $20,683,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ASND. EverSource Wealth Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after buying an additional 91 shares during the period. GAMMA Investing LLC lifted its holdings in Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 102 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after purchasing an additional 143 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 151 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Ascendis Pharma A/S by 1.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company's stock valued at $2,064,000 after buying an additional 159 shares in the last quarter.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of recent analyst reports. TD Cowen decreased their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a "buy" rating on the stock in a report on Wednesday, September 4th. Citigroup lowered their price target on Ascendis Pharma A/S from $193.00 to $178.00 and set a "buy" rating on the stock in a report on Wednesday, September 4th. JPMorgan Chase & Co. cut their price objective on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an "overweight" rating for the company in a report on Wednesday, September 4th. StockNews.com raised shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Thursday, September 5th. Finally, Morgan Stanley raised their target price on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an "equal weight" rating in a research note on Thursday, May 16th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and an average target price of $187.08.

Ascendis Pharma A/S Stock Down 1.6 %

ASND traded down $1.83 during trading hours on Wednesday, reaching $112.93. 758,809 shares of the company's stock traded hands, compared to its average volume of 401,134. The firm has a 50-day moving average price of $133.61 and a 200 day moving average price of $137.33. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The firm has a market capitalization of $6.58 billion, a PE ratio of -11.75 and a beta of 0.63.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.